Natera Inc. (NASDAQ:NTRA) with a market cap of $3 billion is a medical diagnostics company focusing on genetic testing across a range of applications. The company is currently commercializing a number of reproduction and prenatal-related DNA tests that are already industry-leading while expanding into solutions for the oncology field and organ transplant assessments. NTRA has been a big winner this year up 160% based on strong growth and what is seen as still the early stages of a large market opportunity. This article takes a look at recent developments and our view on